Narayana Hrudayalaya (NH) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
22 Apr, 2026Executive summary
Consolidated operating revenue rose 61.2% year-over-year to ₹21,512 Mn in Q3 FY26, with EBITDA up 19.9% to ₹3,904 Mn and PAT at ₹1,281 Mn, reflecting strong growth and the impact of the UK acquisition.
India delivered strong profit growth for the second consecutive quarter, driven by transformation programs and payer mix optimization, resulting in 150-200 bps margin expansion year-over-year.
UK operations, consolidated from November 2025, contributed significant revenue and assets, with margin improvement targeted through operational efficiencies and payer mix shift.
Cayman business continues to grow, with local and international market share opportunities and insurance revenues up 1332% YoY.
Major clinical milestones included a 35% QoQ increase in robotic cardiac surgeries and the first heart transplant in Ahmedabad.
Financial highlights
Consolidated revenue for Q3 FY26 was ₹21,511.70 million, up from ₹13,345.90 million in Q3 FY25; nine-month revenue was ₹53,022.29 million.
Adj. EBITDA for Q3 FY26 was ₹4,662 Mn (+43.1% YoY), margin at 21.7%; Adj. PAT was ₹2,548 Mn (+31.6% YoY), margin at 11.8%.
India revenue: ₹11,796 Mn (+11.8% YoY); Cayman: ₹4,991 Mn (+70% YoY); UK: ₹4,902 Mn (newly consolidated).
Standalone net profit for Q3 FY26 was ₹757.37 million; consolidated net profit was ₹1,280.86 million.
Exceptional item of ₹509.36 million recognized due to increased employee benefit liabilities from new Labour Codes.
Outlook and guidance
Expansion plans target over 7,600 beds by FY30, with multiple greenfield and brownfield projects underway in key regions.
India business aims to sustain current margin levels barring short-term impacts, with double-digit revenue growth expected until new hospitals are commissioned.
Digital transformation and ESG initiatives are expected to drive operational efficiency and sustainability.
No guidance on insurance or integrated care profitability timelines, but optimism on growth trajectory.
The company continues to monitor regulatory changes and will adjust accounting for employee benefits as required.
Latest events from Narayana Hrudayalaya
- Q1 FY25 saw record revenue, margin expansion, and new insurance and hospital launches.NH
Q1 24/2517 Feb 2026 - Q2 FY25 delivered revenue growth, margin gains, digital progress, and expansion plans.NH
Q2 24/2517 Feb 2026 - Q3 FY25 saw strong growth, margin recovery, digital progress, and major expansion investments.NH
Q3 24/2517 Feb 2026 - Strong FY25 revenue, EBITDA, expansion, digital growth, and a Rs. 4.50/share dividend.NH
Q4 24/2517 Feb 2026 - Q1 FY26 delivered strong revenue and margin growth, with expansion and digitalization ongoing.NH
Q1 25/2617 Feb 2026 - Acquisition enables U.K. healthcare growth, margin expansion, and private payer mix increase.NH
M&A Announcement3 Feb 2026 - Q2 FY26 saw strong revenue and profit growth, margin expansion, and a major UK acquisition.NH
Q2 25/2617 Nov 2025